<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489254</url>
  </required_header>
  <id_info>
    <org_study_id>GTR001</org_study_id>
    <secondary_id>2011-000888-27</secondary_id>
    <nct_id>NCT01489254</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of GTR in Comparison to Copaxone®</brief_title>
  <acronym>GATE</acronym>
  <official_title>Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synthon BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synthon BV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer
      acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple
      sclerosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GTR is being developed by Synthon as a similar version of Copaxone®. GTR has a similar
      quantitative and qualitative composition as Copaxone®, with regard to active substance and
      excipients and is presented in the same dosage form (pre-filled syringe containing a solution
      for injection). Introduction of GTR is anticipated to have a price lowering effect and will
      give doctors and patients more choice in the pharmaceutical armamentarium for MS.

      This trial consists of two parts:

      Part 1 is a multi-country, multi-centre, randomized, double-blind, active and
      placebo-controlled, equivalence trial comparing the efficacy and safety and tolerability of
      GTR versus Copaxone® in subjects with RRMS. Eligible subjects will be randomly assigned to
      receive daily 20 mg GTR (Synthon BV), 20 mg Copaxone® (TEVA) or placebo for a period of 9
      months.

      In Part 2, the trial continues as an open-label uncontrolled trial to evaluate efficacy and
      safety of long-term treatment with GTR. Subjects completing the 9-month double-blind period
      will be treated with open-label 20 mg daily GTR for another 15 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of T1-Gadolinium Enhancing Lesions During Months 7-9</measure>
    <time_frame>9 months</time_frame>
    <description>The primary endpoint was the total number of gadolinium enhancing lesions (i.e., the cumulative number of new and persisting gadolinium enhancing lesions) during months 7 through 9.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">794</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>GTR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Copaxone®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glatiramer Acetate (GTR)</intervention_name>
    <description>Glatiramer Acetate (GTR) 20 mg daily, for 9 months (Part 1) followed by additional 15 month treatment period (Part 2)</description>
    <arm_group_label>GTR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glatiramer Acetate (Copaxone®)</intervention_name>
    <description>Glatiramer Acetate (Copaxone), 20 mg daily, for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)</description>
    <arm_group_label>Copaxone®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (daily) for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to sign written Informed Consent;

          -  Female and male subjects aged 18-55 years inclusive at the time of Informed Consent
             signing;

          -  Diagnosis of RRMS according to the revised McDonald criteria;

          -  Expanded Disability Status Scale (EDSS) score of 0.0 up to and including 5.5;

          -  Neurologically stable with no evidence of relapse within 30 days prior to
             randomization;

          -  Experienced at least 1 relapse in the year before first screening assessment;

          -  At least 1 T1-weighted Gadolinium enhancing (T1-GdE) lesion on routine brain MRI taken
             within 3 months of starting screening or on screening brain MRI (as confirmed by
             central imaging laboratory;

          -  Having a routine brain MRI showing maximally 15 T1-GdE lesions if scan is taken
             without subject receiving immuno-modulatory treatment, or a routine brain MRI showing
             maximally 5 T1-GdE lesions when taken while on immuno-modulatory treatment, or a
             screening MRI showing maximally 15 T1-GdE lesions;

          -  Must decline initiation or continuation of treatment with other available
             disease-modifying drugs for MS, for whatever reason, after having been informed about
             their respective benefits and possible adverse events by the investigator;

          -  Female subjects of childbearing potential must agree to practice appropriate
             contraceptive methods as assessed by the investigator.

        Exclusion Criteria:

          -  Any life-threatening, medically unstable or otherwise clinically significant condition
             or findings other than MS, in particular neoplastic disease, seizure disorders, or
             psychiatric disease;

          -  Any clinically significant deviation from reference ranges in laboratory tests;

          -  Positive laboratory test results for human immunodeficiency virus (HIV), HBsAg or HCV
             at screening;

          -  Any significant deviation from reference ranges for hepatic function;

          -  Positive urine drug screen or history of substance abuse within the year before
             screening (any use of illicit or prescription drugs or alcohol constituting an abuse
             pattern in the opinion of the investigator);

          -  Having been treated with or having received

               1. at any time:

                    -  glatiramer acetate, cladribine, rituximab, cyclophosphamide, alemtuzumab, or
                       other immunosuppressive treatments with effects potentially lasting for more
                       than 6 months

                    -  total lymphoid irradiation or bone marrow transplantation

               2. within one year before screening:

                    -  mitoxantrone, but subject cannot be enrolled when mitoxantrone was taken at
                       a cumulative lifetime dosing above 100 mg/m2

               3. within 6 months before screening:

                    -  fingolimod, immunoglobulins and/or monoclonal antibodies (including
                       natalizumab), leflunomide, or putative MS treatments

                    -  chronic oral or injected corticosteroids or injected ACTH (more than 30
                       consecutive days)

               4. within 3 months before screening:

                    -  azathioprine, methotrexate

                    -  plasma exchange

                    -  any other experimental intervention, in particular experimental drugs

               5. within 1 month before screening:

                    -  Interferon-β 1a or 1b

                    -  short-term oral or injectable corticosteroids for treatment of a relapse

                    -  short-term ACTH

          -  Having, in the opinion of the investigator, consecutively failed on efficacy grounds
             two full and adequate courses of accepted treatment modalities (normally at least one
             year of treatment for each);

          -  Pregnancy or breastfeeding;

          -  Known hypersensitivity to gadolinium-containing products, glatiramer acetate or
             mannitol;

          -  Having an estimated glomerular filtration rate (eGFR) &lt; 50 mL/min/1.73m2;

          -  Inability to undergo (repeat) MRI investigations as judged by the investigator, e.g.
             due to claustrophobia, metal implants or fragments, tattoos or permanent make-up;

          -  Any reason why, in the investigator's opinion, the subject should not participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Synthon investigational site 112</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 120</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 130</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 107</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 141</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 106</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 135</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 401</name>
      <address>
        <city>Bitebsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 402</name>
      <address>
        <city>Gomel</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 403</name>
      <address>
        <city>Grodno</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 404</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 407</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 408</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 405</name>
      <address>
        <city>Vitebsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 486</name>
      <address>
        <city>Banja Luka</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 487</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 488</name>
      <address>
        <city>Tuzla</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 204</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 207</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 206</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 202</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 203</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 205</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 208</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 201</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 477</name>
      <address>
        <city>Osijek</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 475</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 476</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 478</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 211</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 217</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 210</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 212</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 215</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 216</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 214</name>
      <address>
        <city>Teplice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 297</name>
      <address>
        <city>Kohtla-Jarve</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 296</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 526</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 527</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 528</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 529</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 530</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 227</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 234</name>
      <address>
        <city>Coppito</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 235</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 516</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 512</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 514</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 515</name>
      <address>
        <city>Morelia</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 547</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 548</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 549</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 550</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 244</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 240</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 241</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 242</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 245</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 247</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 251</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 243</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 248</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 250</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 246</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 249</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 260</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 262</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 263</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 264</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 265</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 266</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 267</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 438</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 435</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 437</name>
      <address>
        <city>Belgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 431</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 445</name>
      <address>
        <city>Kaluga</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 427</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 432</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 447</name>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 446</name>
      <address>
        <city>Lipetsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 571</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 428</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 429</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 434</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 442</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 444</name>
      <address>
        <city>Penza</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 433</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 424</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 420</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 421</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 426</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 430</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 440</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 422</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 441</name>
      <address>
        <city>Tver</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 425</name>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 423</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 450</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 451</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 453</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 452</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 501</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 505</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 502</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 474</name>
      <address>
        <city>Cherkassy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 459</name>
      <address>
        <city>Chernihiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 463</name>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 458</name>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 472</name>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 464</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 468</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 495</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 461</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 469</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 455</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 456</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 496</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 473</name>
      <address>
        <city>Lutsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 462</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 466</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 497</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 498</name>
      <address>
        <city>Mariupol</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 457</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 470</name>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 471</name>
      <address>
        <city>Uzhhorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 465</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 460</name>
      <address>
        <city>Zhytomyr</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 284</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 281</name>
      <address>
        <city>Stoke on Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 283</name>
      <address>
        <city>Torquay</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synthon investigational site 280</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
    <country>Kazakhstan</country>
  </removed_countries>
  <results_reference>
    <citation>Cohen J, Belova A, Selmaj K, Wolf C, Sormani MP, Oberyé J, van den Tweel E, Mulder R, Koper N, Voortman G, Barkhof F; Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE) Study Group. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2015 Dec;72(12):1433-41. doi: 10.1001/jamaneurol.2015.2154.</citation>
    <PMID>26458034</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2011</study_first_posted>
  <results_first_submitted>April 18, 2016</results_first_submitted>
  <results_first_submitted_qc>September 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 31, 2016</results_first_posted>
  <last_update_submitted>November 10, 2016</last_update_submitted>
  <last_update_submitted_qc>November 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis,</keyword>
  <keyword>Relapsing-Remitting Multiple Sclerosis,</keyword>
  <keyword>glatiramer acetate,</keyword>
  <keyword>MRI,</keyword>
  <keyword>lesions,</keyword>
  <keyword>MS relapse rate,</keyword>
  <keyword>Copaxone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were randomized at 118 investigational sites in 17 countries.</recruitment_details>
      <pre_assignment_details>1549 patients were assessed for eligibility of whom 796 subjects were randomized in a 4.3:4.3:1 ratio to receive generic glatiramer acetate (GTR), brand glatiramer acetate (Copaxone) or matching placebo. Two subjects were randomized to the generic glatiramer acetate group but did not start treatment and were not enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Glatiramer 20 mg</title>
          <description>Glatiramer Acetate (GTR) 20 mg daily for 9 months</description>
        </group>
        <group group_id="P2">
          <title>Copaxone 20 mg</title>
          <description>Glatiramer Acetate (Copaxone) 20 mg daily for 9 months</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo (daily) for 9 months</description>
        </group>
        <group group_id="P4">
          <title>Extension Glatiramer 20 mg</title>
          <description>Glatiramer acetate (GTR) 20 mg daily for 15 months, open-label extension</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Part</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="355"/>
                <participants group_id="P2" count="357"/>
                <participants group_id="P3" count="84"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="330"/>
                <participants group_id="P2" count="324"/>
                <participants group_id="P3" count="81"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons for not completing study</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Extension Part</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="728">735 completed the DB part, 729 were eligible to continue in the OL part, 1 opted not to continue</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="670"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons for not completing study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glatiramer 20 mg</title>
          <description>Glatiramer Acetate (GTR) 20 mg daily for 9 months</description>
        </group>
        <group group_id="B2">
          <title>Copaxone 20 mg</title>
          <description>Glatiramer Acetate (Copaxone) 20 mg daily for 9 months</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo (daily) for 9 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="353"/>
            <count group_id="B2" value="357"/>
            <count group_id="B3" value="84"/>
            <count group_id="B4" value="794"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.6" spread="8.6"/>
                    <measurement group_id="B2" value="33.8" spread="9.0"/>
                    <measurement group_id="B3" value="32.6" spread="8.7"/>
                    <measurement group_id="B4" value="33.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="528"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from first clinical event to randomization</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="5.3"/>
                    <measurement group_id="B2" value="6.4" spread="6.0"/>
                    <measurement group_id="B3" value="5.7" spread="6.0"/>
                    <measurement group_id="B4" value="5.9" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of relapses in period within 2 year prior to signing ICF</title>
          <units>Number of relapses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" spread="0.9"/>
                    <measurement group_id="B2" value="1.8" spread="0.9"/>
                    <measurement group_id="B3" value="1.9" spread="0.9"/>
                    <measurement group_id="B4" value="1.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of T1-Gadolinium Enhancing Lesions During Months 7-9</title>
        <description>The primary endpoint was the total number of gadolinium enhancing lesions (i.e., the cumulative number of new and persisting gadolinium enhancing lesions) during months 7 through 9.</description>
        <time_frame>9 months</time_frame>
        <population>Full Analyis Set (FAS): all randomized subjects who received at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer 20 mg</title>
            <description>Glatiramer Acetate (GTR) 20 mg daily for 9 months</description>
          </group>
          <group group_id="O2">
            <title>Copaxone 20 mg</title>
            <description>Glatiramer Acetate (Copaxone) 20 mg daily for 9 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (daily) for 9 months</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of T1-Gadolinium Enhancing Lesions During Months 7-9</title>
          <description>The primary endpoint was the total number of gadolinium enhancing lesions (i.e., the cumulative number of new and persisting gadolinium enhancing lesions) during months 7 through 9.</description>
          <population>Full Analyis Set (FAS): all randomized subjects who received at least 1 dose of trial medication</population>
          <units>Number of lesions</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="353"/>
                <count group_id="O2" value="357"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity analysis - Number of Gd lesions</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="353"/>
                    <count group_id="O2" value="357"/>
                    <count group_id="O3" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" lower_limit="0.31" upper_limit="0.57"/>
                    <measurement group_id="O2" value="0.38" lower_limit="0.28" upper_limit="0.52"/>
                    <measurement group_id="O3" value="0.82" lower_limit="0.57" upper_limit="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Equivalence analysis - Number of Gd lesions</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="353"/>
                    <count group_id="O2" value="357"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="0.34" upper_limit="0.59"/>
                    <measurement group_id="O2" value="0.41" lower_limit="0.31" upper_limit="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Estimates represent the mean total lesions during months 7 through 9 and were estimated from the fitted random effect generalized linear model (longitudinal model) with a negative binomial distribution and logaritmic link function. To assess study sensitivity, data of the active treatment groups and placebo were included in the model, resulting in the ratios and 95% CIs for the combined Glatiramer 20 mg and Copaxone 20 mg treatment group and the individual treatments over placebo.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To conclude study sensitivity the combined active treatment groups Glatiramer 20 mg and Copaxone 20 mg needed to be superior to placebo.</non_inferiority_desc>
            <param_type>Ratio (or Ratio of estimated means)</param_type>
            <param_value>0.488</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.365</ci_lower_limit>
            <ci_upper_limit>0.651</ci_upper_limit>
            <estimate_desc>Ratio of combined Glatiramer 20 mg + Copaxone 20 mg to placebo and 95% confidence interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Estimates represent the mean total lesions during months 7 through 9 and were estimated from the fitted random effect generalized linear model (longitudinal model) with a negative binomial distribution and logaritmic link function including Glatiramer 20 mg and Copaxone 20 mg treatment groups to assess study equivalence.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To conclude equivalence between Glatiramer 20 mg and Copaxone 20 mg, efficacy in the combined active treatment groups needed to be superior to placebo (confirming study sensitivity) and the 2-sided 95% CI for the estimated ratio of Glatiramer 20 mg to Copaxone 20 mg needed to be fully enclosed in the prespecified equivalence margin (0.727 - 1.375).</non_inferiority_desc>
            <param_type>Ratio (or Ratio of estimated means)</param_type>
            <param_value>1.095</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.883</ci_lower_limit>
            <ci_upper_limit>1.360</ci_upper_limit>
            <estimate_desc>Ratio of Glatiramer 20 mg to Copaxone 20 mg and 95% confidence interval.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months + 15 months</time_frame>
      <desc>The safety population consisted of all subjects who received at least 1 injection with study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Glatiramer 20 mg</title>
          <description>Glatiramer Acetate (GTR) 20 mg daily for 9 months, double-blind</description>
        </group>
        <group group_id="E2">
          <title>Copaxone 20 mg</title>
          <description>Glatiramer Acetate (Copaxone) 20 mg daily for 9 months, double-blind</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo (daily) for 9 months, double-blind</description>
        </group>
        <group group_id="E4">
          <title>Extension Glatiramer 20 mg</title>
          <description>Glatiramer acetate (GTR) 20 mg daily for 15 months, open-label extension</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Immediate post-injection reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactoid reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to central nervous sytem</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Benign hydatidiform mole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Radiculitis cervical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Secondary progressive multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="90" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Immediate post-injection reaction</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="728"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="353"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="84"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="728"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Synthon's agreements with its investigators may vary. However, Synthon BV does not prohibit any investigator from publishing. Any publication from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP Clinical Development</name_or_title>
      <organization>Synthon BV</organization>
      <phone>+3124727700</phone>
      <email>clinicaltrials@synthon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

